Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Free Cash Flow Generation Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Free Cash Flow Generation Index of -0.44x as of September 2025. Free cash flow of CN¥-5.06 Million represents 0% of operating cash flow (CN¥11.57 Million). See 301211 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Free Cash Flow Generation Index (2018–2025)
Historical FCF Generation Index trend for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 8 annual periods. Explore Hubei Biocause Heilen Pharmaceutical Co. (301211) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year Free Cash Flow Generation Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For the full company profile including market capitalisation, see Hubei Biocause Heilen Pharmaceutical Co. (301211) total market value.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | -5.93x | CN¥-44.78 Million | CN¥7.55 Million | CN¥52.33 Million | ▼ -733.5% |
| 2024 | -0.71x | CN¥-68.36 Million | CN¥96.07 Million | CN¥164.43 Million | ▼ -97.1% |
| 2023 | -0.36x | CN¥-49.47 Million | CN¥137.06 Million | CN¥186.53 Million | ▼ -151.8% |
| 2022 | 0.70x | CN¥174.84 Million | CN¥250.79 Million | CN¥75.95 Million | ▼ -16.0% |
| 2021 | 0.83x | CN¥102.92 Million | CN¥123.98 Million | CN¥21.07 Million | ▼ -6.7% |
| 2020 | 0.89x | CN¥108.28 Million | CN¥121.67 Million | CN¥13.39 Million | ▼ -2.5% |
| 2019 | 0.91x | CN¥339.98 Million | CN¥372.33 Million | CN¥32.34 Million | ▲ +36.1% |
| 2018 | 0.67x | CN¥51.11 Million | CN¥76.18 Million | CN¥25.08 Million | — |